John Baird, Ph.D.

Chief of Staff to the CEO

John Baird joined PTC in 2008 as a research scientist and has held roles with increasing responsibilities at the company across the research, clinical development, and project management groups.  

In 2021, John joined the Development Leadership Team and in March 2023, was promoted to Chief of Staff to CEO Matt Klein, and joined the Executive Committee leadership team. 

Since 2012, he has served as the Alliance Director for our spinal muscular atrophy (SMA) collaboration with the SMA Foundation and Roche; this collaboration led to the discovery and development of Evrysdi, the world’s first approved small molecule splicing modifier used to treat SMA. John has also managed PTC’s strategic partnerships with Astra Zeneca and the Wellcome Trust. 

John has co-authored a number of scientific peer-reviewed manuscripts over his career and is listed as an inventor on several PTC patents. He has worked across a number of therapeutic areas including genetic disorders, infectious disease and oncology. John earned his B.S. degree in chemistry and his Ph.D. in synthetic organic chemistry from the University of Illinois at Urbana-Champaign.